The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies - Institut Gustave Roussy Accéder directement au contenu
Article Dans Une Revue Science Année : 2018

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

Résumé

The fine line between human health and disease can be driven by the interplay between host and microbial factors. This ``metagenome'' regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Fichier principal
Vignette du fichier
Zitvogel2018.pdf (436.4 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-01791568 , version 1 (04-05-2022)

Identifiants

Citer

Laurence Zitvogel, Yuting Ma, Didier Raoult, Guido Kroemer, Thomas F. Gajewski. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science, 2018, 359 (6382, SI), pp.1366-1370. ⟨10.1126/science.aar6918⟩. ⟨hal-01791568⟩
373 Consultations
845 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More